Immunosuppressant

Everolimus Granules – Available as Nanoparticles with 2.68% & 5% Strengths.

• MKPPL is the first to come up with pellet based approach for immune suppressants.
• Facilitates direct filling into capsules and can be easily employed in tableting. Nano particles can be effectively used for manufacturing of ointments (Tacrolimus) and solutions (Everolimus).
• MKPPL pellet advantages includes using a micro emulsion technology. No cyclization of the drug, hence less delta lactones formation.
• Coated pellets, hence the formulator does not require a contained facility for finished formulation.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Mycophenolate mofetil (MMF) is a immunosuppressant and product of mycophenolic acid, used extensively in transplant medicine, and it may play an increasing role in autoimmune disease. MMF has been introduced as a novel immunosuppressive agent in systemic lupus erythematosus (SLE), often in patients intolerant of or resistant to conventional immunosuppressive regimens.

Sirolimus (initially known as Rapamycin) is a macrolide antibiotic with immunosuppressant properties. It is typically used to prevent rejection of organ transplantations especially in kidney transplants. Sirolimus has an anti-proliferative effect which makes it an effective treatment option for mesothelioma.

Tacrolimus IR Pellets 0.5%, 1%, 5% – Suitable for Capsules (Dose: 0.5 mg, 1 mg, 5 mg)

• Tacrolimus is a potent immune suppressant. Tacrolimus is the first of the LIMUS based immunosuppressant to be marketed as a solid dosage capsule, infusion and ointment.
• Murli Krishna Pharma’s technology addresses all the three formulations of Tacrolimus.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.